Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.32 |
| ▸ | KDM5A | P29375 | 5/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9933638 | 1.00 | CCR5 (0.34) | CCR5MAP4K4KDM5ATRPA1LMNA | |
| SCHEMBL1769262 | 0.84 | CCR5 (0.42) | CCR5MAP4K4DPP4 | |
| SCHEMBL9965903 | 0.80 | GPR119 (0.43) | — | |
| SCHEMBL12836236 | 0.80 | GPR119 (0.43) | — | |
| SCHEMBL9934284 | 0.80 | HCRTR1 (0.40) | — | |
| SCHEMBL9933425 | 0.79 | HCRTR1 (0.38) | DPP4 | |
| SCHEMBL9933427 | 0.79 | HCRTR1 (0.38) | DPP4 | |
| SCHEMBL22194731 | 0.78 | TRPA1 (0.36) | TRPA1 | |
| SCHEMBL22194734 | 0.78 | TRPA1 (0.36) | TRPA1 | |
| SCHEMBL22194735 | 0.78 | TRPA1 (0.36) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | CCR5 299/4885MAP4K4 1606/4885KDM5A 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.